Brevan Howard Capital Management’s Sana Biotechnology SANA Stock Holding History

Brevan Howard Capital Management’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$152K	Sell	52,810 -17,797	-25%	-$70.1K	﹤0.01%	1965
2025 Q4	$287K	Buy	+70,607	New	+$316K	﹤0.01%	1395
2025 Q3	–	Sell	-260,723	Closed	-$712K	–	2238
2025 Q2	$712K	Buy	260,723 +120,016	+85%	+$248K	﹤0.01%	1217
2025 Q1	$236K	Buy	140,707 +67,081	+91%	+$188K	﹤0.01%	932
2024 Q4	$120K	Buy	+73,626	New	+$220K	﹤0.01%	950
2024 Q3	–	Sell	-46,296	Closed	-$253K	–	1398
2024 Q2	$253K	Buy	+46,296	New	+$369K	﹤0.01%	827

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Brevan Howard Capital Management's SANA Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Sana Biotechnology (SANA) stake by 25% in Q1 2026, selling an estimated $70.1K and leaving 52,810 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Brevan Howard Capital Management first reported a position in SANA in Q2 2024 and has held it in 6 quarters since. The position peaked at $712K in Q2 2025. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

Brevan Howard Capital Management held 52,810 shares of Sana Biotechnology worth $152K as of Q1 2026.
Brevan Howard Capital Management sold 17,797 Sana Biotechnology shares in Q1 2026, an estimated $70.1K.
Sana Biotechnology made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1965 holding.
Brevan Howard Capital Management first reported a position in Sana Biotechnology in Q2 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Sana Biotechnology position peaked at $712K in Q2 2025.
202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.